Document Detail

Therapeutic reactivation of mutant p53 protein by quinazoline derivatives.
MedLine Citation:
PMID:  21912889     Owner:  NLM     Status:  Publisher    
Purpose The human tumour suppressor protein p53 is mutated in nearly half of human tumours and most mutant proteins have single amino acid changes. Several drugs including the quinazoline derivative 1 (CP-31398) have been reported to restore p53 activity in mutant cells. The side chain of 1 contains a styryl linkage that compromises its stability and we wished to explore the activity of analogues containing more stable side chains. Methods Reactivation of p53 function was measured by flow cytometry as the ability to potentiate radiation-induced G(1)-phase cell cycle arrest and by western blotting to determine expression of p21(WAF1). DNA binding was measured by competition with ethidium and preliminary pharmacological and xenograft studies were carried out. Results Screening of analogues for potentiation of radiation-induced G(1)-phase cell cycle arrest using NZOV11, an ovarian tumour cell line containing a p53(R248Q) mutation, demonstrated that the (2-benzofuranyl)-quinazoline derivative 5 was among the most active of the analogues. Compound 5 showed similar effects in several other p53 mutant human tumour cell lines but not in a p53 null cell line. 5 also potentiated p21(WAF1) expression induced by radiation. DNA binding affinity was measured and found to correlate with p53 reactivation activity. Plasma concentrations of 5 in mice were sufficient to suggest in vivo activity and a small induced tumour growth delay (7 days) of NZM4 melanoma xenografts was observed. Conclusion Compound 5 restores p53-like function to a human tumour cells lines expressing a variety of mutant p53 proteins, thus providing a basis for the design of further new drugs.
Hamish S Sutherland; In Young Hwang; Elaine S Marshall; Brent S Lindsay; William A Denny; Catherine Gilchrist; Wayne R Joseph; Debra Greenhalgh; Emma Richardson; Philip Kestell; Angela Ding; Bruce C Baguley
Related Documents :
6343379 - Induction of indoleamine 2,3-dioxygenase in alveolar interstitial cells of mouse lung b...
4003939 - Increases in airway reactivity to histamine and inflammatory cells in bronchoalveolar l...
19484389 - An open-access microfluidic model for lung-specific functional studies at an air-liquid...
11237429 - Establishment and characterization of a human b cell line from the lung tissue of a pat...
24639559 - Neurogenesis during development of the vertebrate central nervous system.
8003339 - Cell number and distribution in human and rat airways.
4549039 - Accelerated cell death produced by a cholera cytotoxin on isolated epithelial cells fro...
20079729 - The depletion of skeletal muscle satellite cells with age is concomitant with reduced c...
22954369 - Intracellular chemical gradients: morphing principle in bacteria.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-9-13
Journal Detail:
Title:  Investigational new drugs     Volume:  -     ISSN:  1573-0646     ISO Abbreviation:  -     Publication Date:  2011 Sep 
Date Detail:
Created Date:  2011-9-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8309330     Medline TA:  Invest New Drugs     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Aza-derivatives of resveratrol are potent macrophage migration inhibitory factor inhibitors.
Next Document:  Posterior cortical atrophy with prominent alexia without agraphia in a Tourette syndrome.